

## Learner Notification

### Society of Gynecologic Oncology

2022 Welcoming Spaces – Module #8 Hormone Considerations in Transgender Patients with Gynecologic Cancer

Enduring: July 25, 2022 – July 25, 2023

Online

#### Acknowledgement of Financial Commercial Support

GSK Astra Zeneca

Seagen Merck

#### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

#### Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

#### Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Physicians (ACCME) Credit Designation

Amedco LLC designates this **enduring material** for a maximum of **1.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of **1.0 Enduring ANCC** contact hours.

#### Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of **1.0 Enduring** knowledge-based CPE contact hours.

**NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

#### Objectives - After Attending This Program You Should Be Able To

1. Review the general standards of what's "normal" in cross-gender hormone therapy patients with an endocrinologist.
2. Explore risks and benefits of cross-gender hormones to consider if a transgender patient elects to use them.
3. Discuss how to counsel a patient about hormone therapy before and during cancer treatment with a gynecologic oncologist.
4. Compare the risks vs. benefits of using hormone therapy when it is historically "contraindicated."

#### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

First Name	Last Name	Do you have any financial relationships with ineligible companies to disclose?
Allison	Asante	Nothing to Disclose
Ethel Dawn	Capone	Nothing to Disclose
Don	Dizon	Clovis, Regeneron, Pfizer, Oasmia & Asta Zeneca - Consultant
Monique	Gary	Nothing to Disclose
Cecilia	Hardacker	Nothing to Disclose

Bill	Jesdale	Nothing to Disclose
Teri	Jordan	Nothing to Disclose
Aurea	Kasberg	Bristol Myers Squibb, Servier, GlaxoSmithKline, & Genentech - Grant Recipient
Lisa	Kaszubski	Nothing to Disclose
Nina	Kennedy	Nothing to Disclose
Allison	Knuth	Nothing to Disclose
Knoll	Larkin	Nothing to Disclose
Pam	Lewis	Nothing to Disclose
Minghao	Liu	Nothing to Disclose
Phoenix	Matthews	Nothing to Disclose
Jennifer	Meade	Nothing to Disclose
Lauren	Nocera	Nothing to Disclose
Gwendolyn	Quinn	CME Outfitter - Speakers' Bureau, Honoraria/Reimbursement
BJ	Rimel	GSK, AstraZeneca, & Merck - Advisory Board Participant; Deep6AI, & Tempus - Consultant
Polly	Rossi	Nothing to Disclose
Tracy	Sandstrom	Nothing to Disclose
NFN	Scout	Syros Pharmaceuticals, Servier Pharmaceuticals, Bristol Myers Squibb, Glaxo Smith Klein, & Genentech - Grant Recipient
Zul Surani	Surani	Nothing to Disclose
Karl	Surkan	Nothing to Disclose
Christopher	Wheldon	Nothing to Disclose
Erin	Zink	Nothing to Disclose